AstraZeneca Extends RSV Deal With Aussie Biotech Biota
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-based Biota's 2005 antiviral collaboration and license agreement with MedImmune has been picked up by AstraZeneca and expanded to include a number of Asian territories, Biota announced Aug. 25